DK2790717T3 - Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein - Google Patents

Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein Download PDF

Info

Publication number
DK2790717T3
DK2790717T3 DK12857691.5T DK12857691T DK2790717T3 DK 2790717 T3 DK2790717 T3 DK 2790717T3 DK 12857691 T DK12857691 T DK 12857691T DK 2790717 T3 DK2790717 T3 DK 2790717T3
Authority
DK
Denmark
Prior art keywords
collagen
methods
binding polypeptide
pth
pthrp receptor
Prior art date
Application number
DK12857691.5T
Other languages
Danish (da)
English (en)
Inventor
Joshua Sakon
Ranjitha Katikaneni
Tulasi Ponnapakkam
Takaki Koide
Robert C Gensure
Sagaya Theresa Leena Philominathan
Osamu Matsushita
Nozomu Nishi
Original Assignee
Univ Arkansas
The Kitasato Inst
Montefiore Med Center
Univ Kagawa Nat Univ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas, The Kitasato Inst, Montefiore Med Center, Univ Kagawa Nat Univ Corp filed Critical Univ Arkansas
Application granted granted Critical
Publication of DK2790717T3 publication Critical patent/DK2790717T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
DK12857691.5T 2011-12-14 2012-12-14 Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein DK2790717T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161570620P 2011-12-14 2011-12-14
US201261596869P 2012-02-09 2012-02-09
PCT/US2012/069831 WO2013090770A2 (en) 2011-12-14 2012-12-14 Delivery of therapeutic agents by a collagen binding protein

Publications (1)

Publication Number Publication Date
DK2790717T3 true DK2790717T3 (da) 2018-07-30

Family

ID=48613370

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12857691.5T DK2790717T3 (da) 2011-12-14 2012-12-14 Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein
DK18173596.0T DK3391899T3 (da) 2011-12-14 2012-12-14 Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18173596.0T DK3391899T3 (da) 2011-12-14 2012-12-14 Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein

Country Status (7)

Country Link
US (3) US9579273B2 (enExample)
EP (4) EP4397755A3 (enExample)
JP (5) JP6366507B2 (enExample)
CA (2) CA2859412C (enExample)
DK (2) DK2790717T3 (enExample)
ES (3) ES2816009T3 (enExample)
WO (1) WO2013090770A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2155874T3 (en) 2007-04-09 2016-08-01 Univ Arkansas FUSION PROTEIN OF COLLAGE BINDING DOMAIN AND parathyroid hormone
ES2816009T3 (es) * 2011-12-14 2021-03-31 Univ Arkansas Administración de agentes terapéuticos mediante una proteína de unión a colágeno
US9526765B2 (en) 2012-02-09 2016-12-27 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
WO2018148573A1 (en) * 2017-02-10 2018-08-16 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
GB201706781D0 (en) 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide
KR101964376B1 (ko) * 2017-09-29 2019-04-01 주식회사 나이벡 부갑상선호르몬(parathyroid hormone, PTH)에 골조직 선택성 펩타이드가 결합되어 있는 융합 펩타이드를 포함하는 약학 조성물 및 생체재료
JP7045166B2 (ja) * 2017-11-07 2022-03-31 株式会社ニッピ コラーゲン結合材、その製造方法、ドラッグデリバリーシステム、および担持体
WO2019173829A1 (en) 2018-03-09 2019-09-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Delivering biological drugs to tissues
US20220363778A1 (en) * 2019-08-28 2022-11-17 The Research Foundation For The State University Of New York Targeted delivery of tumor matrix modifying enzymes
JP7774276B2 (ja) * 2020-09-02 2025-11-21 コラジェン・ファーマ株式会社 ペプチドを含む組成物及びその用途
US12403179B2 (en) 2021-02-18 2025-09-02 The Board Of Trustees Of The University Of Arkansas Release of growth factors at wound healing stages
AU2023298113A1 (en) * 2022-06-27 2025-01-16 Sustain Holdings, Llc Collagen peptide-based medicament compositions and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
WO1994022468A1 (en) 1993-04-02 1994-10-13 Anticancer, Inc. Method for delivering beneficial compositions to hair follicles
WO1998004591A1 (en) 1996-07-31 1998-02-05 The General Hospital Corporation Novel parathyroid hormone-related peptide analogs
US20100267012A1 (en) * 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
US6387663B1 (en) 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
US7601685B2 (en) 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
EP1151116A1 (en) 1999-02-19 2001-11-07 Terumo Kabushiki Kaisha Collagen-binding physiologically active polypeptide
US20020102709A1 (en) 1999-02-19 2002-08-01 Tetsuya Ishikawa Collagen-binding physiologically active polypeptide
US6908994B1 (en) 1999-05-10 2005-06-21 The Texas A&M University System Collagen-binding proteins from enterococcal bacteria
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20040053368A1 (en) 2000-08-15 2004-03-18 Tetsuya Ishikawa Collagen-binding hybrid polypeptide
JP2002058485A (ja) * 2000-08-16 2002-02-26 Terumo Corp コラーゲン結合性を有する骨形成促進融合蛋白質
JP4560291B2 (ja) 2001-12-18 2010-10-13 イジュノシッヒ テクニッヒ ホッフシューラ チューリッヒ 組織操作のための成長因子改変タンパク質マトリクス
JP4750416B2 (ja) 2002-07-25 2011-08-17 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン受容体の活性化と造血前駆細胞の増殖
ES2269973T3 (es) 2003-02-13 2007-04-01 Synthes Ag Chur Mezcla inyectable para sustituir un tejido oseo.
US20040220094A1 (en) 2003-05-01 2004-11-04 Skinner Keith K. Inverse agonist and agonist peptides that stimulate/inhibit hair growth
EP1680073B1 (en) 2003-10-21 2013-01-02 IGF Oncology, LLC Compounds and method for treating cancer
WO2005046798A1 (en) 2003-11-12 2005-05-26 Nps Allelix Corp. Treatment of bone loss utilizing full length parathyroid hormone
EP1557176A1 (en) 2004-01-26 2005-07-27 Ferring B.V. Treatment of bone metastases by means of PTH receptor agonists
WO2005078085A1 (ja) * 2004-02-16 2005-08-25 Techno Network Shikoku Co., Ltd. コラーゲン様構造を有するポリペプチド
US20090005298A1 (en) 2004-02-27 2009-01-01 The University Of Western Ontario Bone Sialoprotein Collagen-Binding Peptides
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
EP1812082B1 (en) 2004-10-21 2013-08-14 IGF Oncology, LLC Toxins and radionuclides coupled to IGF-1 receptor ligands for the treatment of cancer
WO2006073711A2 (en) 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
ATE514712T1 (de) * 2005-12-26 2011-07-15 Yantai Zhenghai Bio Technology Co Ltd Aktivierte collagen-gerüstmaterialien und ihre speziellen kondensierten aktiven restorationsfaktoren
CA2669914C (en) * 2006-11-16 2017-11-07 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
WO2008101406A1 (en) * 2007-02-14 2008-08-28 Yolare Dermaceuticals, Llc Modified mutant collagenase and it's use in fat melting and in scar reduction
WO2008123166A1 (en) * 2007-03-20 2008-10-16 Nsk-Warner K.K. Roller-type one-way clutch
DK2155874T3 (en) * 2007-04-09 2016-08-01 Univ Arkansas FUSION PROTEIN OF COLLAGE BINDING DOMAIN AND parathyroid hormone
EP2178905B1 (en) * 2007-07-26 2013-11-06 Allergan, Inc. Methods of activiting clostridial toxins
US20100159564A1 (en) * 2007-11-30 2010-06-24 Dwulet Francis E Protease resistant recombinant bacterial collagenases
JP5400336B2 (ja) 2008-08-04 2014-01-29 トヨタ紡織株式会社 表皮材の成形装置
US10545149B2 (en) 2008-10-06 2020-01-28 Morehouse School Of Medicine Detection of HIV-related proteins in urine
JP2010172247A (ja) 2009-01-29 2010-08-12 Kitasato Institute 積層型高密度培養人工組織の製造方法及び積層型高密度培養人工組織
WO2011060431A2 (en) * 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
JPWO2011142425A1 (ja) 2010-05-12 2013-07-22 国立大学法人 香川大学 上皮層含有組織の再生材および再生評価方法
ES2385239B1 (es) * 2010-09-30 2013-06-19 Proteos Biotech S.L.U. Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
AU2012227790C1 (en) * 2011-03-16 2016-06-30 Meiji Seika Pharma Co., Ltd. Probe for analyzing biological tissue and method for utilizing same
JP5512887B2 (ja) 2011-05-13 2014-06-04 学校法人北里研究所 成長因子アンカーリング型骨移植材料および成長因子アンカーリング型骨移植材料製造用キット
ES2816009T3 (es) * 2011-12-14 2021-03-31 Univ Arkansas Administración de agentes terapéuticos mediante una proteína de unión a colágeno
EP4015627B1 (en) * 2012-01-12 2023-09-27 Endo Global Ventures Clostridium histolyticum enzyme
WO2013120030A1 (en) * 2012-02-08 2013-08-15 Shining Golden Yida Welding & Cutting Machinery Manufacture Ltd. Rotary vane air motor with improved vanes and other improvements
US9526765B2 (en) * 2012-02-09 2016-12-27 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
EP2937088B1 (en) * 2012-12-21 2020-11-18 Tokushima University Composition having tissue repairing activity and utilization thereof
WO2015048334A2 (en) * 2013-09-25 2015-04-02 Pronutria, Inc. Edible species nutritive polypeptides and methods of production and use thereof
US9539363B2 (en) * 2014-04-24 2017-01-10 Warsaw Orthopedic, Inc. Collagen matrix
WO2016060252A1 (ja) * 2014-10-16 2016-04-21 学校法人北里研究所 神経再生用移植材料、神経再生用移植材料の製造方法、及び神経再生用移植材料製造用キット
EP3112474A1 (en) * 2015-06-29 2017-01-04 Evonik Degussa GmbH Method of detecting avian necrotic enteritis
US10513696B2 (en) * 2016-05-24 2019-12-24 Hamzeh Alipour Lucilia sericata collagenase
CN109789189B (zh) * 2016-09-29 2024-01-23 阿森迪斯药物骨疾病股份有限公司 控释pth化合物的剂量方案
WO2018148573A1 (en) * 2017-02-10 2018-08-16 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
WO2019113123A1 (en) * 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
US10519236B2 (en) * 2018-01-23 2019-12-31 New York University Antibodies specific to delta 1 chain of T cell receptor
WO2019173829A1 (en) * 2018-03-09 2019-09-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Delivering biological drugs to tissues
CN112996506A (zh) * 2018-08-14 2021-06-18 奥斯特克有限公司 吡咯并二吡啶化合物

Also Published As

Publication number Publication date
EP3391899A1 (en) 2018-10-24
DK3391899T3 (da) 2020-08-24
JP2022023162A (ja) 2022-02-07
US20190249163A1 (en) 2019-08-15
US20170204390A1 (en) 2017-07-20
CA3113972A1 (en) 2013-06-20
JP2018104461A (ja) 2018-07-05
CA2859412A1 (en) 2013-06-20
JP6697019B2 (ja) 2020-05-20
EP3808365A1 (en) 2021-04-21
JP2015513312A (ja) 2015-05-07
US11279922B2 (en) 2022-03-22
EP2790717A2 (en) 2014-10-22
EP4397755A3 (en) 2025-01-01
EP2790717A4 (en) 2016-03-09
EP2790717B1 (en) 2018-05-30
EP3391899B1 (en) 2020-07-15
US20140377215A1 (en) 2014-12-25
EP3808365C0 (en) 2024-01-31
EP4397755A2 (en) 2024-07-10
CA3113972C (en) 2023-08-01
ES2975215T3 (es) 2024-07-04
JP6366507B2 (ja) 2018-08-01
JP2023153154A (ja) 2023-10-17
WO2013090770A3 (en) 2014-12-31
US9579273B2 (en) 2017-02-28
EP3808365B1 (en) 2024-01-31
US11001820B2 (en) 2021-05-11
ES2816009T3 (es) 2021-03-31
CA2859412C (en) 2021-05-25
JP2020073554A (ja) 2020-05-14
WO2013090770A2 (en) 2013-06-20
ES2695161T3 (es) 2019-01-02
JP7327765B2 (ja) 2023-08-16

Similar Documents

Publication Publication Date Title
DK2790717T3 (da) Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein
WO2007143098A3 (en) Hepatocyte growth factor (hgf) binding proteins
WO2007143090A3 (en) Hepatocyte growth factor (hgf) binding proteins
AU2018260809A1 (en) Compounds and uses thereof for the modulation of hemoglobin
UA113856C2 (xx) Злитий білок для лікування порушень метаболізму
MX349198B (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
MX377317B (es) Compuestos de hormona de crecimiento humana recombinante unidos a peg.
NZ602734A (en) Therapeutic dll4 binding proteins
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
NZ598524A (en) Therapeutic dll4 binding proteins
GB201201314D0 (en) Composition
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
MX2010009743A (es) Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
WO2010095118A3 (en) A cosmetic treatment method including the projection of an image onto the zone to be treated
MX2014003676A (es) Proteinas de doble funcion para el tratamiento de trastornos metabolicos.
MX2019000586A (es) Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
GEP20176629B (en) Glucagon/glp-1 receptor co-agonists
NZ603570A (en) Biological materials related to her3
EP2274437A4 (en) COMPOSITIONS AND METHODS FOR DETECTION OF EGFR MUTATIONS IN CASES OF CANCER
WO2008142303A3 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
GEP20196969B (en) New therapeutical composition containing apomorphine as active ingredient
MX2013005182A (es) Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr.